Health economic analysis of bevacizumab + paclitaxel versus paclitaxel alone as first-line treatment for metastatic breast cancer
Background The Norwegian Knowledge Centre for the Health Services has been commissioned by Norwegian Directorate of Health's Cancer Programme to make an assessment of the cost per progression-free year gained associated with the use of bevacizumab in combination with paclitaxel versus paclitaxe...
| Otros Autores: | |
|---|---|
| Formato: | Libro electrónico |
| Idioma: | Inglés |
| Publicado: |
Oslo :
Norwegian Knowledge Centre for the Health Services
2009.
|
| Materias: | |
| Ver en Biblioteca Universitat Ramon Llull: | https://discovery.url.edu/permalink/34CSUC_URL/1im36ta/alma991009816712806719 |
